HDAC4/HDAC5/HDAC9 anticorps
-
- Antigène Tous les produits HDAC4/HDAC5/HDAC9
- HDAC4/HDAC5/HDAC9 (HDAC4,HDAC5,HDAC9)
-
Reactivité
- Humain
-
Hôte
- Lapin
-
Clonalité
- Polyclonal
-
Conjugué
- Cet anticorp HDAC4/HDAC5/HDAC9 est non-conjugé
-
Application
- Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), ELISA
- Réactivité croisée
- Humain, Souris
- Purification
- Antibodies were produced by immunizing rabbits with synthetic peptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific peptide.
- Immunogène
- Peptide sequence around aa.244~248/257~261/218~222 (T-A-S-E-P) derived from Human HDAC4/HDAC5/HDAC9.
- Isotype
- IgG
-
-
- Indications d'application
- WB:1:500-1:1000, IHC:1:50-1:200, IF:1:100-1:200,
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Buffer
- Supplied at 1.0 mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.
- Agent conservateur
- Sodium azide
- Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Stock
- -20 °C,-80 °C
- Stockage commentaire
- Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
- Antigène
- HDAC4/HDAC5/HDAC9 (HDAC4,HDAC5,HDAC9)
- Autre désignation
- HDAC4/HDAC5/HDAC9 (HDAC4/HDAC5/HDAC9 Produits)
- Synonymes
- anticorps AHO3, anticorps BDMR, anticorps HA6116, anticorps HD4, anticorps HDAC-4, anticorps HDAC-A, anticorps HDACA, anticorps histone deacetylase 4, anticorps HDAC4
- Sujet
-
Background:
Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Involved in muscle maturation via its interaction with the myocyte enhancer factors such as MEF2A, MEF2C and MEF2D.
Cress, W.D. and Seto, E. (2000) J Cell Physiol 184, 1-16.
Vigushin, D.M. and Coombes, R.C. (2004) Curr. Cancer Drug Targets 4, 205-218.
Marmorstein, R. (2001) Cell Mol Life Sci 58, 693-703.
Thiagalingam, S. et al. (2003) Ann. N.Y. Acad. Sci. 983, 84-100.Aliases: HD4/HD5/HD9
- UniProt
- P56524, Q9UQL6, Q9UKV0
-